News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts. WEEKLY
The Benefits and Challenges of PEGylating Small Molecules
Polyethylene glycol (PEG) conjugation is a highly effective technical and commercial strategy to develop macromolecules. The authors explain the benefits and process of PEGylation and how it may be applied to small molecules.
A versatile technology based on repeating units of polyethylene glycol (PEG), known as PEGylation, was first described in
the literature in 1977 (1). PEG is a water-soluble, amphiphilic, nontoxic, and nonimmunogenic compound. It is safely cleared
from the body and is currently a component of seven approved macromolecular drugs administered parenterally. Although the
primary use of PEGylation has been to improve the physicochemical properties of large molecules, it may also be used with
small molecules, provided certain challenges are met.
STOCKBYTE/GETTY IMAGES
Small molecules have few sites to which PEGs can be attached without compromising their functionality. In addition, small
molecules generally are delivered orally, and formulators believed that PEGylation would compromise oral bioavailability.
These challenges have heretofore prevented the technology from being tried successfully on small molecules. A large-PEG prodrug
approach to small-molecule PEGylation was unsuccessful. The strategy of permanently attaching a small PEG to a small molecule
is unteseted and counterintuitive because low molecular weights are generally favored. These challenges in PEGylating small
molecules have been overcome, however.
PEGs can be designed with various pharmacokinetic-altering architectures. They can be synthesized as linear, branched, or
forked structures with functional groups at one or more termini to enable several conjugation strategies. Linkers covalently
attach the molecule to the parent drug directly or indirectly. The choice of linkers enables PEG to be placed in various positions
on the molecule. Placement can fine tune a drug's pharmacokinetic properties and maintain its efficacy. Overall, PEGylated
molecules demonstrate enhanced solubility and stability, on the shelf and in vivo, and an improved safety profile.
Table I: Potential benefits of PEG technology.
Conjugation bonds can be stable or releasable to create entirely new compounds or novel prodrugs. Stable PEG linkages create
new pharmaceutical entities with respect to such pharmacokinetic parameters as circulating half life, clearance, absorption,
and bioavailability. PEGs may harm the pharmacodynamic properties of target binding because of steric hindrance. The releasable
attachments used in PEG prodrugs enable controlled drug release through the choice of architecture, attachment sites, and
linker molecules.
Table II: PEGylated macromolecular drugs.
PEGylation imparts valuable, and in some cases crucial, pharmacokinetic properties to macromolecules, whether stable molecules
or prodrugs, and has emerged as the dominant strategy for improving macromolecular drugs. PEGylation is associated with numerous
clinical benefits in these drugs, including increased efficacy, decreased side effects, and lower frequency of dosing (see
Table I). Table II shows the current, macromolecular PEG landscape. The technology is applicable to many therapeutic areas
(e.g., oncology, metabolic diseases, and infectious diseases) and to various macromolecular classes (e.g., cytokines, antibodies,
enzymes, and aptamers).
Timothy Riley, PhD, is vice-president of PEGylation research at Nektar Therapeutics, 490 Discovery Dr., Huntsville, AL 35806, tel. 800.457.1806, fax 256.533.4805.
Articles by Timothy Riley
Jennifer Riggs-Sauthier
Jennifer Riggs-Sauthier is director of science and technology at Nektar Therapeutics, 490 Discovery Dr., Huntsville, AL 35806.
Articles by Jennifer Riggs-Sauthier
Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
